Cellular uptake and distribution of cobalt complexes of fluorescent ligands

The development of complexes that allow the monitoring of the release and distribution of fluorescent models of anticancer drugs initially bound to cobalt(III) moieties is reported. Strong quenching of fluorescence upon ligation to cobalt(III) was observed for both the carboxylate- and the hydroximate-bound fluorophores as was the partial return of fluorescence following addition of ascorbate and cysteine. The extent of the increase in the fluorescence intensity observed following addition of these potential reductants is indicative of the fluorophore being displaced from the complex by the action of ascorbate or cysteine, by ligand exchange. The cellular distribution of the fluorescence revealed that coordination to cobalt can dramatically alter the subcellular distribution of a bound fluorophore. This work shows that fluorescence can be an effective means of monitoring these agents in cells, and of determining their sites of activation. The results also reveal that the cytotoxicity of such agents correlates with their uptake and distribution patterns and that these are influenced by the types of ligands attached to the complex.

[1]  M. Ghosh,et al.  Electron transfer. 115. Reduction of cobalt-bound superoxide with ascorbate , 1992 .

[2]  S. Rockwell,et al.  Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Minna,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. , 1987, Cancer research.

[4]  Roger L. Lundblad,et al.  Handbook of Biochemistry and Molecular Biology, Fifth Edition , 2010 .

[5]  Zbigniew Staszak,et al.  Synthesis, spectroscopic and magnetic studies of chromium(II) complexes isolated from in vitro reduction of the chromium(VI) ion with the main cellular reductants ascorbic acid, cysteine and glutathione* , 1992 .

[6]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[7]  B. Culver,et al.  Respiratory Physiology: The Essentials, 7th edition. , 2006 .

[8]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[9]  K. Okamoto,et al.  Synthesis, characterisation and polynuclearisation reaction of trans (S)-[Co(aminothiolate- N , S ) 2 (en)]-type cobalt( III ) complexes with 2-aminoethanethiolate, L -cysteinate and D -penicillaminate , 1999 .

[10]  G. Webb,et al.  Complexes of Nickel(II)with a Cyclic Tetradentate Secondary Amine , 1965 .

[11]  L. H. Gray,et al.  The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. , 1953, The British journal of radiology.

[12]  G. Anderegg,et al.  Pyridinderivate als Komplexbildner VIII Die Herstellung je eines neuen vier‐ und sechszähnigen Liganden , 1967 .

[13]  W. Denny.  The role of hypoxia-activated prodrugs in cancer therapy. , 2000, The Lancet. Oncology.

[14]  F. Cotton,et al.  Basic Inorganic Chemistry , 1976 .

[15]  W. Denny,et al.  Design and synthesis of cobalt(III) nitrogen mustard complexes as hypoxia selective cytotoxins. The X-ray crystal structure of bis(3-chloropentane-2,4-dionato)(RS-N,N′-bis(2-chloroethyl)ethylenediamine)cobalt(III) perchlorate, [Co(Clacac)2(bce)]ClO4 , 1991 .

[16]  W. Denny,et al.  Synthesis, structures and hypoxia-selective cytotoxicity of cobalt(III) complexes containing tridentate amine and nitrogen mustard ligands , 2000 .

[17]  T. Hambley,et al.  Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug. , 2007, Chemistry.

[18]  J. Lilie,et al.  Kinetics of ammonia detachment from reduced cobalt(III) complexes based on conductometric pulse radiolysis , 1974 .

[19]  B. Teicher,et al.  Cytotoxicity, radiosensitization, antitumor activity, and interaction with hyperthermia of a Co(III) mustard complex. , 1990, Cancer research.

[20]  T. Hambley,et al.  Models of hypoxia activated prodrugs: Co(III) complexes of hydroxamic acids. , 2006, Dalton transactions.

[21]  K. Wetterhahn,et al.  In vitro reaction of the carcinogen chromate with cellular thiols and carboxylic acids , 1985 .

[22]  John B. West,et al.  Respiratory Physiology - the Essentials , 1979 .

[23]  H. Tajmir-Riahi.  Vitamin C interaction with cobalt-ammine cations. Synthesis, spectroscopic and structural characterization of cobalt-pentammine and cobalt-tetrammine sugar complexes containing L-ascorbate anion. , 1986, Biophysical chemistry.

[24]  A. S. Reddy,et al.  A convenient method for the preparation of hydroxamic acids , 2000 .

[25]  S. Lippard,et al.  New metal complexes as potential therapeutics. , 2003, Current opinion in chemical biology.

[26]  W. Denny,et al.  Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. , 1993, Journal of medicinal chemistry.

[27]  B. Douglas,et al.  Synthesis and spectroscopic characterization of cobalt(III) and copper(II) complexes of hexadentate and tetradentate ligands containing pyridyl arms , 1988 .

[28]  A. Gough,et al.  Retinal Degeneration in Rats Induced by CI-1010, a 2-Nitroimidazole Radiosensitizer , 1998, Toxicologic pathology.

[29]  D. T. Sawyer,et al.  Voltammetric evaluation of the effective acidities (pKa') for Brønsted acids in aprotic solvents. , 1984, Analytical chemistry.

[30]  W. Wilson,et al.  Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. , 2000, Toxicology and applied pharmacology.

[31]  J. Burgess,et al.  KINETICS OF OXIDATION OF ASCORBATE BY TETRANUCLEAR COBALT(III) COMPLEXES ('HEXOLS') IN AQUEOUS SOLUTION , 1996 .